gbola amusa md cfa head hc research
sale trade et
sale trade et
share mil
creat bluematrix
diamond rough
initi coverag provent buy rate
potenti pipelin treat prevent autoimmun
inflammatori diseas provent develop intervent
patient earli stage diseas limit tissu destruct patholog
goal delay prevent chronic inflamm achiev
compani in-licens asset drug develop
includ janssen johnson johnson compani unrat
unrat mani candid repurpos reviv
demonstr target engag signal efficaci
clinic trial miss endpoint initi studi lead
asset teplizumab monoclon antibodi mab
treatment type diabet prime exampl
long histori academ big pharma trial on-going phase
protect studi provent seek improv
past result target patient earlier time post-diagnosi util
altern endpoint base signal seen previous data
phase ii nih-sponsor studi util teplizumab
at-risk subject degre rel patient announc
june demonstr earli intervent profound effect
time diseas onset delay year although small
studi result publish nejm demonstr
therapeut modul diseas progress strongli support
provent approach treat autoimmun diseas earli stage
compani also test intercept prevent strategi
on-going phase iia studi crohn diseas
addit clinic trial lupu celiac diseas due begin
given recent valid early-intervent strategi see
consider opportun upsid particularli
see figur key reason optim
partli derisk assets/studi design base previou trial
use c-peptid endpoint
support equiti invest manufactur etc origin
drug develop includ johnson johnson amgen
distinct potenti disease-modifi mechan action
report top-line piia data crohn
therapi rel standard-of-car
multipl opportun success could lead upsid
pleas refer import disclosur inform regul analyst certif found page report
initi phase ib mad studi healthi volunt
file ind prevent
file ind initi phase iib trial non-respons celiac diseas
report top-line data piii protect studi
report top-line data piib studi non-respons celiac diseas
price target base probability-adjust model key franchis use dcf wacc
perpetu growth impli termin ebitda multipl deriv price target
npv/share type diabet assum novel immunotherapi
use newly-diagnos pediatr us patient assum take volum share
novel immunotherapi initi us price per year launch assum
european sale repres us sale lag rest world sale european sale
lag appli launch probabl deriv mm global risk-adjust sale forecast
npv/share celiac diseas celiac diseas assum novel immunotherapi
use non-respons celiac diseas us patient assum take volum
share novel immunotherapi initi us price per year launch assum
european sale repres us sale lag rest world sale european sale
lag appli launch probabl deriv mm global risk-adjust sale forecast
intern program npv/share model npv/share use crohn diseas
npv/share use system lupu erythematosu npv/share pipelin
net cash per share npv/share provent cash posit recent stood mm
risk achiev target price
clinic mani asset provent develop shown limit clinic efficaci previou trial
studi progress test differ indic endpoint potenti higher-than-usu risk failur
studi addit safeti signal may aris earlier-stag asset test
extens human util non-antibody-bas modal
regulatori endpoint provent on-going clinic trial may appropri suffici
registr regulatori agenc could lead delay uncertainti compani pipelin delay could
expos project price target downward revis
competit potenti provent asset may substanti expect could possibl due
competit autoimmun space includ market product well asset earlier develop
big pharma includ johnson johnson unrat type diabet roch unrat bristol-my squibb
unrat glaxosmithklin unrat unrat unrat celgen unrat johnson johnson
crohn diseas unrat johnson johnson lupu compani work
unrat unrat lando biopharma privat immus privat
intellectu properti base recent file patent protect provent asset licens
unrat unrat johnson johnson vactech privat begin expir
possibl extens asset protect beyond termin valu may affect
commerci competit standard care therapi like gener steroid and/or rise biosimilar
relev may constrain uptak provent asset addit compani build sale market
medic affair infrastructur us possibl global region provent need establish
manufactur capac commerci suppli beyond clinic trial capac alreadi secur
financ provent may need rais addit capit prior achiev profit accomplish via
equiti financ may result share dilut sharehold
stock price volatil share price volatil common development compani biotechnolog sector
page
provent prvb clinical-stag compani focus develop asset intercept prevent autoimmun
inflammatori diseas compani util multipl strategi includ biolog small molecul vaccin
achiev goal current provent in-licens advanc monoclon antibodi
type diabet monoclon antibodi celiac diseas small molecul
inhibitor crohn diseas bispecif antibodi addit compani
develop polyval coxsackieviru vaccin prevent type diabet acut infect provent
incorpor
page
summari provent give autoimmun asset new leas life
risk provent thesi
chardan type diabet model model mm risk-adjust sale npv/share
chardan celiac diseas model model mm risk-adjust sale npv/sh
chardan crohn diseas model model mm risk-adjust sale npv/sh
chardan sle model model mm risk-adjust sale npv/sh
sensit analysi success would drive greatest upsid base current model
catalyst pipelin provent data throughout key celiac data due
teplizumab type diabet earli intervent improv outcom
type diabet autoimmun condit lead destruct insulin-produc cell pancrea
progress stage current therapi address symptomat diseas
design elimin autoreact cell activ promot toler
previou studi teplizumab met endpoint potenti due heterogen pt characterist
long-term follow-up studi demonstr c-peptid preserv suggest durabl benefit
on-going provent phase trial integr best featur previou trial
trial util teplizumab at-risk asymptomat patient confirm efficaci earli intervent
provent also take approach true prophylaxi type diabet much earlier develop
work limit inflamm celiac diseas prevent small intestin destruct
celiac diseas autoimmun diseas character gluten-induc blunt small intestin villi
avoid gluten treatment celiac diseas effect patient necessit better option
one inflammatori effector underli celiac diseas make potenti therapeut target
test multipl clinic trial indic clean safeti signal efficaci
reduc patient-report symptom paramet piia piib expand
oral inhibitor coloni stimul receptor limit inflamm
macrophage-induc inflamm contribut patholog crohn diseas
effect phase iia studi ra shown efficaci mous model crohn
inhibit cell activ may limit symptom lupu autoantibody-driven diseas
sale key product
page
summari provent give autoimmun asset new leas life
initi coverag provent buy rate possibl opportun afford earli
intervent approach autoimmun use partli derisk asset achiev goal provent develop
pipelin immunomodul intercept prevent immun mediat diseas includ type
diabet celiac diseas crohn diseas lupu goal program target pathway essenti
progress diseas interven earli order prevent tissu destruct loss cell pancrea
block immune-medi kill success could true disease-modifi therapi delay prevent
progress rather standard care approach typic target effector molecul chronic inflammatori
stage diseas provent candid licens drug develop allow compani save
 cost expedit data readout part compani strateg vision reach go/no-go decis program
quickli either advanc refocu pipelin time- capital-effici manner flip-sid strategi
howev increas risk mani asset fail meet endpoint least one clinic trial see merit
overal strategi howev provent util inform prior studi find appropri subset
patient choos altern trial endpoint order maxim opportun efficaci success approach
could yield signific upsid investor model suggest success could drive valuat
success celiac diseas could drive stock price lead asset teplizumab mab
stori histori discov well-known immunologist dr jeff blueston univers chicago
ucsf dr kevan herold yale univers develop clinic unrat
licens unrat discontinu meet endpoint phase ii/iii trial
provent licens teplizumab may initi phase protect trial
april util c-peptid endpoint rather use previous top-line data due
recent data phase ii trialnet studi at-risk individu mostli degre rel
patient diabetes-associ antibodi dysglycemia demonstr delay diseas onset year prv-
compar placebo-tr subject figur evid immune-modul chang
cours support provent overal early-intervent approach autoimmun diseas therapi compani
also run phase iia trial inhibitor receptor licens janssen
johnson johnson compani unrat use crohn diseas data anticip asset licens
ulcer coliti discontinu provent may phase ib trial met safeti efficaci
endpoint studi bispecif antibodi use lupu licens
mab licens unrat celiac diseas vaccin
prevent licens vactech privat slate begin
base data gener thu far overal approach see potenti substanti upsid base
potenti develop disease-modifi therapi interven earli target critic pathway
select patient and/or endpoint demonstr efficaci previou trial endpoint post-hoc analysi
efficaci signal multipl investigator-sponsor trial trialnet board seat jeff blueston
sever opportun success pipelin could send price see figur
equiti invest big pharma partner owner pledg next rais
page
provent steadi flow catalyst remaind data crohn next data figur
report top-line phase iia data crohn diseas
initi phase ib multipl ascend dose studi healthi volunt ahead trial lupu
file ind prevent type diabet
report top-line data protect phase studi newly-diagnos
asset develop capit effici potenti consider success provent virtual compani
 facil limit expenditur equip etc busi model effici use fund
invest clinical-stag program could yield mid- late-stag data year time-frame rather lengthi
preclin experi safeti studi risk develop asset falter previou studi
investor abil toler risk upsid potenti signific see figur upsid success
type diabet celiac diseas view reward could great limit downsid current valuat
target patient earli cours diseas provid uniqu nich may provid differenti outcom
develop biolog inflammatori autoimmun diseas competit area mix success
approach thu far howev focus control neutral effector like cytokin later
stage diseas inflamm chronic fulmin provent differenti other focus
earlier stage diseas biomark autoimmun inflamm present patholog yet sever
approach theori allow provent target differ patient key subset would newly-diagnos
individu rather bulk preval popul would also allow compani potenti captur
signific market share current model rather conserv incorpor multipl competitor also note
mani trial specif target newly-diagnos patient like provent also see like
asset limit inflamm tissu destruct earli diseas patient would benefit substanti term
qualiti life potenti save hospit and/or addit therapi demonstr trialnet
indic test allow natur expans new market success mani autoimmun diseas
share common featur overproduct canon proinflammatori cytokin cell macrophag
product deposit autoantibodi patient one autoimmun diseas significantli like
develop multipl manifest immun dysfunct relev exampl concord celiac
diseas type base overlap across indic may opportun expans certain
asset addit patient popul diseas market rel eas would align provent
broader strategi would provid derisk life cycl manag opportun compani
invest stakehold suggest confid surfac revisit asset limit evid efficaci
may attract proposit provent back sever origin drug maker
support addit effort johnson johnson innov invest compani seri
stake compani vactech also owner pledg mm equiti invest part
agreement co-develop addit detail compani recent provent util
exist drug suppli janssen contribut
product respect futur use us suggest compani see licens
asset clinically/commerci viabl help derisk compani pipelin
herold kc et al antibodi teplizumab rel risk type diabet new engl
page
risk provent thesi
chang subset patient treat trial endpoint may improv efficaci outcom asset
fundament risk inher provent approach develop previously-fail asset
unsuccess particularli relev chang hand sever time miss endpoint
phase complet discontinu drop limit success
modifi tissu patholog celiac diseas given asset form greatest proport price target
downsid risk sensit analys figur demonstr failur would
substanti effect perform also note target indic broadli challeng target pharmaceut
develop numer failur type diabet sle etc produc consider skeptic cynic
also add risk name
competit certain indic quit high even earli stage develop current model limit valu
crohn diseas sle base intens competit indic even restrict
competit novel target disease-modifi pathway exist approv therapi still
identifi strategi could draw patient away provent asset compani focu earlier stage
patient indic provid point differenti visibl time understand
if/how differ program crohn sle particularli asset develop big pharma
either later-stag result avail determin strategi viabl phase beyond obtain
addit inform patient subset challeng model greater upsid program
uptak product may poor due competit standard care lack marker patient identif
key featur provent platform develop drug earli intervent autoimmun diseas rather
treatment chronic inflammatori phase diseas post-tissu destruct differenti strategi
uniqu challeng patient identif mani autoimmun diseas progress slowli diagnos
substanti period time monitor symptom sle celiac diseas therefor may challeng identifi
patient earli cours diseas without robust routin screen procedur may difficult disrupt
current treatment paradigm condit like crohn diseas begin treatment escal
courses/typ steroid well-accept inexpens depend efficaci profil provent
drug may challeng introduc early-stag biolog intervent
ip protect may run sooner desir mani asset develop number year
particularli patent protect pipelin begin expir start bar
extens still opportun commerci exclus soon-to-b off-pat drug may present
challeng novel asset particularli rise biosimilar
lack success multipl asset may limit interest compani strategi provent model allow oper
virtual compani without intern research develop capac capital-effici model may
yield dramat upsid multipl failur may challeng busi model without intern innov qualiti asset
may lower competitor could contribut limit commerci success long term
page
adapt provent may corpor present chardan
figur highlight provent pipelin type diabet program portfolio also contain number phase phase ii asset see particular valu
page
chardan type diabet model model mm risk-adjust sale npv/share
figur type diabetesw model launch initi price us excerpt lead mm risk-adjust sale
page
million prvb unit state sale prvb million sale prvb yoy statespopul diabet incid diabet diabet incid diabet patient case diagnos per case diagnos per year novel patient treat novel share follow-on share golimumab ustekinumab share share pec-direct share novel treat sale yoy provent inc
chardan celiac diseas model model mm risk-adjust sale npv/sh
figur model launch initi price us excerpt lead mm risk-adjust sale
page
million prvb unit state sale prvb million sale prvb yoy statespopul diseas incid diseas incid celiac diseas preval celiac diseas preval novel patient treat novel share share share share share novel treat sale yoy provent inc
chardan crohn diseas model model mm risk-adjust sale npv/sh
figur model launch initi price us excerpt lead mm risk-adjust sale
page
million prvb unit state sale prvb million sale prvb yoy statespopul crohn incid crohn crohn preval crohn adult patient moderate-to-sever incid adult patient moderate-to-sever novel crohn patient treat novel share share share modul ozanimod share jak inhibitor filgotinib upadacitinib share novel treat price sale yoy provent inc
chardan sle model model mm risk-adjust sale npv/sh
figur model launch initi price us excerpt lead mm risk-adjust sale
page
million prvb unit state sale prvb million sale prvb yoy statespopul preval preval new case per year treat novel sle patient treat novel share share share share approv immunomodul ustekinumab share novel immunotherapi lupuzor cenerimod sle patient treat sale prvb yoy provent inc
sensit analysi success would drive greatest upsid base current model
figur chang valuat driven success/penetr clinical-stag asset provent pipelin
page
abcdprvb valuat assum per year success base case valuat assum per year success base case valuat assum per year success base case valuat assum per year success base case provent inc
catalyst pipelin provent data throughout key celiac data due
figur catalystslead asset enter phase trial data come asset readout throughout
page
dateeventchardan inhibitor oral pcd piia trial moderate-to-sever crohn diseaseth primari endpoint chang crohn diseas activ scale inhibitor oral report top-lin result piia studi crohn concern safeti efficaci base ra bab iv initi phase ib mad studi healthi volunteersth phase ia sad studi demonstr good toler target polyval cvb vaccin im file ind initi clinic studiesthi vaccin could use acut infect mab sc submit ind initi phase iib celiac diseas popul non-respons celiac diseas high unmet runway suffici fund project oper requir middl line bab iv initi phase iia studi lupu patientsthi test patient trial may includ sle lupu nephriti bab iv report result phase ib mad studyif still limit cell deplet multipl dose would polyval cvb vaccin im initi trial safeti studi ensur advers respons vaccin polyval cvb vaccin im report top-line interim result trial endpt safeti toler endpt measur mab sc initi possibl pediatr trial celiac diseas particularli vulner popul high unmet mab iv pcd phase protect trial recent-onset entail cours dose month apart final readout mab sc report top-line phase iib result celiac diseas trial like test abil prevent gluten-induc tissu mab iv report result phase protect studi measur chang c-peptid improv patent expiri could bring expriy far bispecif antibodi mab monoclon antibodi mad multipl ascend dose pcd primari complet date endpoint ra rheumatoid arthriti sad singl ascend dose sc subcutan sle system lupu erythematosu type diabet provent inc
figur asset span stage develop provent steadi flow catalyst clinic result
page
product candidatenear-term milestonesww bispecif antibodi iv system lupu erythematosu sle /autoimmun diseas initi phase ib mad trial healthi volunt initi phase iia trial lupu patient report top-line data phase ib studyprovent coxsacki viru vaccin im type diabet prevention/acut coxsacki infect prevent file ind initi trial report top-line interim resultsprovent stage developmentpreclinphas small molecul inhibitor oral crohn diseas pcd phase iia studi report top-lin result phase iia studyprovent ibd janssen buy-back monoclon antibodi iv early-onset type diabet pcd phase protect studi report top-line result phase protect studyprovent monoclon antibodi sc celiac diseas continu chronic toxicolog studi file ind initi phase iib trial report top-line phase iib resultsprovent buy-back right provent inc
teplizumab type diabet earli intervent improv outcom
type diabet autoimmun condit lead destruct insulin-produc cell
autoimmun condit cellular infiltr
autoantibodi product lead damag death cell
also histor known juvenil diabet refer
typic age onset unlik type diabet gener
diagnos later life incid peak
year age
current estim suggest mm american
incid steadili rise time world-wide
yearli diagnosi us approxim patient
underli caus remain elus mani factor show
genet associ identifi particularli
hla mhc locu key protein immun recognit
involv differenti regulatori cell
involv immun cell traffick involv cell
activ protein tune cell
caus rise incid poorli understood
thought involv environment factor rather genet
chang within popul
potenti contributor includ dysbiosi
microbiom viral infect exposur certain food
like egg cow milk
adapt katsar et al chardan
figur character cell- antibody-medi autoimmun respons
time destroy pancreat cell lead insulin insuffici
rewer ludvigsson environment risk factor type diabet lancet
page
progress stage current therapi address symptomat diseas
mani autoimmun diseas natur histori
biomark incit immun respons
preced tissu damag inflamm
earliest sign includ presenc
autoantibodi islet/ cell antigen low-
level loss cell
islet destruct increas hyperglycemia
becom detect absenc
symptom often measur lead oversight
underli defect
patient symptomat
limit proport function cell
remain diseas reach point
diagnos insulin replac therapi
current therapeut intervent limit
symptomat phase diseas continu glucos monitor
insulin infus standard care patient
remain one approv treatment
number strategi test includ
teplizumab fail demonstr substanti
modif certain diseas biomark patient
activ symptomat diseas
limit treatment option none
diseas modifi halt delay cell loss
adapt katsar et al atkinson et al chardan
figur diseas progress even absenc symptom intervent
avail later-stag diseas therapeut develop success yet
page
design elimin autoreact cell activ promot
adapt waldron-lynch kc herold sadelain et al chardan
figur key compon cell receptor complex block modul signal may drive chang cell differenti cytokin profil
key downstream signal compon cell receptor tcr relay signal drive cell activ
treatment antibodi thought act pathogen auto-react cell anti-inflammatori regulatori cell
effector cell either recogn islet antigen thought caus apoptosi due strong activ signal
drive transient deplet inflammatori cell
also possibl treatment drive intern and/or shed tcr cell surfac case cell would unabl
recogn antigen limit inflammatori respons without actual kill cell
treatment also drive induct anti-inflammatori regulatori cell cell limit autoimmun
respons product tgf-
order reduc side effect fc portion teplizumab modifi prevent bind fc receptor alter decreas cytokin releas
syndrom seen previou version antibodi
waldron-lynch kc herold immunomodulatori therapi preserv pancreat -cell function type diabet drug discov
page
previou studi teplizumab met endpoint potenti due heterogen pt
adapt sherri et al chardan
figur one key efficaci studi phase ii/iii teplizumab fail meet primari endpoint stratifi patient demonstr c-peptid preserv
sherri et al teplizumab treatment type diabet protg studi result random placebo-control trial lancet
page
studi intern trial patient type diabet age year old primari endpoint composit
level insulin dose chang baselin
although patient characterist balanc across treatment group includ diagnosi within week fewer still rang
autoantibodi c-peptid area curv auc author note particular certain geograph popul india
sever diseas base metric compar other like us
younger patient patient us preserv c-peptid pronounc total patient popul
suggest case cell destruct less profound efficaci teplizumab might greater
similarli full-dos teplizumab seem alter insulin dose cutoff despit lack overal chang insulin dose baselin
although post-hoc subgroup analys elimin fact overal trial fail us seem justif revis
studi util stringent criteria particularli patient earlier post-diagnosi higher c-peptid level
data pool multipl phase ii trial support assess figur
adapt provent april corpor present chardan
figur chang c-peptid treatment replic across multipl studi although magnitud chang rang fairli wide
page
long-term follow-up studi demonstr c-peptid preserv suggest durabl
adapt perdigoto al et al chardan
figur long-term follow demonstr higher c-peptid even year post-treat daili insulin use lower throughout treatment year
agreement import c-peptid readout potenti efficaci teplizumab subset patient year follow-up data
abat trial indic respond initi analysi maintain significantli higher level c-peptid control non-
normal baselin account differ diseas durat c-peptid mainten among respond even signific
respond patient also maintain significantli lower insulin use throughout trial period metric compar
control non-respond year post-treat
continu dose howev benefit treatment may maintain long-term
herold kc et al teplizumab mab treatment preserv c-peptid respons patient new-onset type diabet random control trial diabet
perdigoto al et al treatment type diabet teplizumab clinic immunolog follow-up year diagnosi diabetologia
page
on-going provent phase trial integr best featur previou
adapt provent may corpor present chardan
figur on-going phase teplizumab trial conduct earlier onset patient younger averag age
base subgroup analys present compani move forward phase trial focus earlier onset
patient week sinc diagnosi younger patient popul year old
outcom trial also focu c-peptid rather endpoint auc c-peptid mixed-m toler test
c-peptid shown preserv multipl studi make reason benchmark
importantli therapi type diabet gener approv metric either alon composit
insulin hypoglycem incid american diabet associ ada recommend use c-peptid primari
endpoint type diabet trial given concord -cell function c-peptid secret equimolar ratio insulin
longer-liv blood
public base review current research evalu new therapi type diabet group intern
expert conven ada conclud assess -cell function measur c-peptid level suitabl primari
outcom pivot intervent studi therapi aim preserv -cell function patient type diabet
secondari endpoint includ insulin use also lower teplizumab previou trial glycem control includ time target rang
number clinically-relev hypoglycem episod
note trial also longer durat studi month follow-up rather month
may advantag efficaci sustain dose month apart possibl effect drug
decreas final studi visit
palmer jp et al c-peptid appropri outcom measur type diabet clinic trial preserv -cell function diabet
page
trial util teplizumab at-risk asymptomat patient confirm efficaci earli
adapt trial net herold kc et al chardan
figur phase ii trial teplizumab subject stage demonstr remark delay diagnosi year rel placebo
herold kc et al antibodi teplizumab rel risk type diabet new engl
page
trialnet sponsor studi patient at-risk develop determin prophylact effect preserv islet cell
phase ii studi enrol subject year old rel thu higher risk
autoantibodi posit impair glucos toler stage diseas determin block cell respons prior
symptomat diseas would prevent delay diseas onset treatment cours teplizumab infus day patient monitor
data publish nejm june present annual ada meet teplizumab found significantli delay onset
year treat subject rel placebo evid diseas progress alter earli immun modul
averag time diagnosi placebo patient month compar subject receiv teplizumab month annual
rate diagnosi placebo group vs teplizumab arm
notabl safeti signal lymphopenia relat mechan action rash spontan resolv
patient signal also seen previou trial
may yet viabl identifi at-risk subject real world studi small result clearli demonstr benefit
earli intervent chang natur histori valid believ on-going phase protect trial patient week post-
diagnosi show greater efficaci previou trial studi test cours treatment addit dose may produc robust result
page
provent also take approach true prophylaxi type diabet much earlier
one factor associ incid type diabet enterovir infect
enter virus infect cell directli cell express certain vial entri
receptor includ polioviru receptor coxsackie-
hypothesi around associ infect type
diabet suggest anti-vir immun respons particularli cell
becom activ due product cytokin like interferon
activ cell virus-specif drive clearanc infect
certain bystand cell somewhat specif self-antigen
islet recogn viral epitop mimick self-antigen also
becom activ begin cycl destruct may lead diseas
anti-cvb antibodi also associ protect type diabet
thought pre-exist immun group virus prior
onset cellular infiltr islet may promot viral clearanc upon
reinfect limit futur insul cell destruct
provent develop pan-coxsackieviru vaccin prophylact
licens vactech juli
compani estim effect could prevent case
murin studi demonstr vaccin effect
prevent virus-induc islet destruct limit side-effect
vaccin could also use acut infect autoimmun
adapt boettler von herrath provent corpor present
figur cvb infect associ incid prevent
diseas provent plan initi trial
diseas associ cvb
compani plan file ind studi start
challeng strategi could identifi subject risk need
boettler von herrath protect trigger type diabet differ role viral infect expert clin immunol
page
work limit inflamm celiac diseas prevent small intestin destruct
celiac diseas autoimmun diseas character gluten-induc blunt small intestin
adapt celiac org sollid jabri chardan
figur celiac diseas caus blunt villi small intestin driven complex immun respons dietari gluten
celiac diseas autoimmun diseas complex etiolog patholog notabl atrophi villi small intestin immune-medi
kill epitheli cell driven consumpt gluten protein found complex starch mani grain notabl wheat patient
celiac diseas often malnourish result poor small intestin absorpt also increas risk addit autoimmun diseas
caus celiac diseas genet environment certain variant hla close associ diseas readili
accommod gluten peptid present immun cell cell account diseas incid celiac diseas also
character autoantibodi transglutaminas well elev number gluten-specif cell intra-epitheli
lymphocyt well high level proinflammatori cytokin like type interferon
sollid lm jabri trigger driver autoimmun lesson coeliac diseas immunol
page
avoid gluten treatment celiac diseas effect patient necessit better
current treatment avail patient celiac diseas consumpt
gluten-fre diet avoid gluten-induc inflammation/patholog
theori work patient real-world evid suggest
case
demonstr flow-chart figur diagnosi celiac diseas
base factor includ biopsi genet analysi hla type respons
certain patient consumpt gfd resolv villu atrophi va
substanti proport patient gfd-adher
patient accord sansotta et al gfd also elimin
symptom diseas
caus continu va despit gfd consumpt
contamin gluten-fre food trace gluten
patient patholog truli non-respons refractori gfd
patient consid non-respons celiac diseas nrcd
s/he continu persist symptom elev antibodi
small intestin damag even follow strict gluten free diet
month case treatment exist amelior
adapt leonard et al sansotta et al chardan
figur gluten-fre diet gfd elimin symptom
celiac diseas patient
leonard mm et al indic use gluten contamin elimin diet patient non-respons celiac diseas nutrient
sansotta et al celiac diseas symptom resolut effect gluten free diet pediatr gastroenterol nutr
page
one inflammatori effector underli celiac diseas make potenti therapeut
adapt jabri abadi chardan
figur trans-present activ cytotox cell promot inflamm
pro-inflammatori cytokin relat util
uniqu receptor subunit differenti express
member famili util
receptor subunit common chain
compon express surfac
effector cell nk cell
receptor subunit
also express transport cell surfac along
either immun cell like myeloid
cell non-immun lineag like stromal epitheli
unlik cytokin solubl order
express must transport
surfac bound
orient receptor one
cell separ cell call trans-
present featur exclus
promot inflamm multipl mechan
includ drive induct cell loss
regulatori cell recruit granulocyt licens
cytotox cell kill
provent collabor unrat
develop antibodi attempt shut
pathway amelior intestin inflamm
jabri abadi function danger signal regul tissue-resid cell tissu destruct immunol
page
test multipl clinic trial indic clean safeti signal efficaci
adapt provent
figur test trial celiac diseas past
licens novemb previous call test number autoimmun indic includ
psoriasi rheumatoid arthriti ra recent non-respons type ii refractori celiac diseas
across studi treatment gener well-toler indic treatment-induc immun suppress result block il-
activ common advers event inject site reaction resolv
type ii refractori celiac diseas patient includ infect mostli resolv
treatment patient immuno-compromis baselin increas possibl neg side effect
previou trial howev fail meet primari endpoint includ psoriasi effect ra
respons suffici diverg placebo celiac diseas base inabl reduc gluten-induc injuri small intestin gfd-
control reduct refractori
signal clinic efficaci note howev merit develop discuss
page
reduc patient-report symptom paramet piia piib expand
adapt provent may corpor present chardan
figur high-dos treatment improv ced-pro
significantli rel placebo phase iia suggest efficaci
phase iia studi patient celiac diseas challeng gluten
treatment mg dose subcutan inject significantli
lower report symptom score ced-pro rel placebo-tr patient
importantli compani consid approv endpoint late-stag
evid support come regulatori preced set
fda allow alba innov
biopharmaceut unrat util patient-report outcom
primari endpoint phase iib studi larazotid
acet celiac diseas
report gastroenterolog regulatori
endpoint advanc workshop state fda
repres reinforc patient report symptom
appropri end point clinic trial drug
approv reliev distress adher gfd initi key end
point would show drug allow gluten consum
note half sentenc howev might present
problem seem directli refer non-respons
popul base challeng endpoint
consider maintain conserv po
beyond self-report symptom score patient also improv gastrointestin
symptom diarrhea iel count physician global assess
provent intend initi phase iib studi non-respons celiac
diseas patient potenti pediatr studi
phase iib enrol patient dose cohort placebo
primari endpoint ced-pro secondari endpoint includ
safeti measur inflamm histolog chang
page
oral inhibitor coloni stimul receptor limit inflamm
macrophage-induc inflamm contribut patholog crohn
adapt rogler rie ch et al chardan
figur reduc macrophage-driven inflamm compon resolv inflammatori bowel disease/crohn diseas therapeut target mani site
coloni stimul factor cytokin produc constitut mesenchym epitheli cell act drive monocyt differenti
macrophag dendrit cell specif set featur receptor receptor tyrosin kinas transduc signal
recently-discov ligand may also contribut macrophag differenti and/or diseas
cancer express macrophag tumor associ poor respons treatment due anti-inflammatori tumor
microenviron inflammatori bowel diseas macrophag associ inflamm cell number
cytokin express level diseas flare significantli higher healthi patients/tissu
given increas express diseas hypothes signal could contribut inflamm
design oral therapi limit activ pathway inhibit tyrosin kinas receptor domain
strategi test well domain context well
klebl fh et al express macrophage-coloni stimul factor normal inflammatori bowel diseas intestin pathol
ch et al target agent clinic develop cancer therapi curr opin pharmacol
rogler resolut inflamm inflammatori bowel diseas lancet gastroenterol hepatol
page
effect phase iia studi ra shown efficaci mous model
adapt genoves mc et al marshal et al chardan
figur phase ii trial shown reduc macrophag number suggest target engag mice treatment protect chemically-induc coliti
licens provent johnson johnson septemb previous test phase iia studi
rheumatoid arthriti ra patient limit signal efficaci
primari endpoint chang diseas activ score c-reactiv protein valu unchang week treatment
trial howev signal target engag includ increas serum due lack receptor-medi endocytosi
reduct number monocyt figur suggest biolog affect readout sensit
also test phase studi hodgkin lymphoma remain develop oncolog janssen
provent on-going phase iia trial crohn diseas test effect crohn diseas activ index endpoint
scale incorpor metric object patient-report outcom measur week treatment
mous studi suggest efficaci dss-induc cell transfer model coliti support develop indic
ra trial safeti signal us could concern particularli elev ast/alt creatin kinas lactat
elev may due inhibit kupffer cell treatment elev associ increas bilirubin
hy law signal see possibl futur sae could influenc success/us
genoves mc et al result phase iia parallel group studi oral inhibitor patient activ rheumatoid arthriti despit disease-modifi
marshal et al blockad coloni stimul lead inhibit dss-induc coliti inflamm bowel
page
inhibit cell activ may limit symptom lupu autoantibody-driven diseas
bi-specif antibodi target fcriib bcr co-receptor unknown
mani autoimmun diseas driven autoantibodi deposit tissu
activ complement system therebi lead tissu damag
one diseas characterist system lupu
erythematosu sle anti-dna anti-nuclear antibodi caus
inflamm skin organ particularli kidney lupu nephriti
treatment sle limit glucocorticoid help earli
symptom via immunosuppress cell-target therapi like
belimumab anti-baff limit cell activ off-label rituximab
deplet cell shown util limit later-stag diseas
origin develop licens provent
may bi-specif antibodi target receptor surfac cell
 cell receptor bcr co-receptor inhibitori fcriib
inhibit prevent downstream activ signal recognit
self-antigen activ block bcr signal
build idea elimin cell signal amelior diseas
improv upon treatment like rituximab activ deplet
also util autoimmun diseas beyond sle
test pia sad studi healthi vol
drug well-toler sae report also
adapt kaul et al chardan
figur sle driven least part cell activ product
autoantibodi lead tissu destruct
evid cell inhibit downregul surfac bcr
yet evid therapeut efficaci howev make
potenti riskier provent asset compani plan initi pib
mad studi piia studi sle patient
pandya et al safeti toler function activ dart molecul target follow singl dose administr healthi
page
figur provent bioincom statement million except ep
page
million except gener oper incom incom incom incom incom incom basic dilut ep ep cash shareholdersdividend size incom gener oper incom incom incom incom incom incom provent inc
sale key product
figur provent bioproduct revenu million
page
figur provent biodiscount cash flow dcf analysi million
page
million except per share net depreci capit increas work defer non-cash free cash first year cash unlev free cash period discount period discount year mid-year factor free cash valu unlev free cash pv forecast unlev free cash valu perpetu growth valu termin termin ebitda xenterpris valu per dilut assumptionswacc calculationsbal sheetdcf valu alloc product cash fiscal year end fiscal year end project discount project discount per cash per dilut share price valu per perpetu growth market cap prvb may share exercis share exercis model dilut million provent inc
